Wikipedia -WSS

Wikipedia

author：comprehensive 2025-08-11 11:42:19 - browse：2946

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

A group of advisers to the Food and Drug Administration voted in favor of Alnylam Pharmaceuticals’ treatment for a debilitating heart disease Wednesday, but only after a day-long debate challenging whether the drug’s modest observed effects were actually meaningful for patients.

The group of independent experts voted 9-3 that the benefits of Alnylam’s drug, called patisiran, outweighed its risks for patients with ATTR-CM, a progressive disease that leads to fatal heart failure if left untreated. The FDA, which is not required to follow the advice of advisers, is expected to make a final decision on patisiran by Oct. 8.

“It’s like a light wind blowing in favor of patisiran over placebo,” said David Cella, a neurologist at the Northwestern University Feinberg School of Medicine who voted in favor of patisiran. David Moliterno, a cardiologist at the University of Kentucky, added that “the good news in this story is that while there may be a small benefit, it doesn’t look like there’s a signal for harm.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： AI models in health care face new federal disclosure requirements

WSS

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

CMS should re

Dario to buy mental health app maker Twill in cash and stock deal

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

hotspot

Wikipedia

Wikipedia

Duchenne breakthrough therapy leaves behind pioneering families

After sickle

Supreme Court strikes down use of affirmative action

FDA approves world's first CRISPR

Medicare details structure of new drug price negotiation program

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

The Harvard botanist who searched for psychedelics in the Amazon

State Dept. review finds Biden bears some blame for Afghanistan failures

STAT letters to the editor on burnt

knowledge

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

CMS should re

Ed Silverman on new gene therapies, biosimilars, coffee, and more

STAT readers on older presidents, polypills, Medicare, and more

Leukemia patients are helped by Syndax's new type of therapy

Dario to buy mental health app maker Twill in cash and stock deal

leisure time

knowledge

focus

Wikipedia